1. Home
  2. ADMA vs BEAM Comparison

ADMA vs BEAM Comparison

Compare ADMA & BEAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo ADMA Biologics Inc

ADMA

ADMA Biologics Inc

N/A

Current Price

$13.26

Market Cap

2.5B

Sector

Health Care

ML Signal

N/A

Logo Beam Therapeutics Inc.

BEAM

Beam Therapeutics Inc.

N/A

Current Price

$20.92

Market Cap

2.8B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
ADMA
BEAM
Founded
2004
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.5B
2.8B
IPO Year
2012
2019

Fundamental Metrics

Financial Performance
Metric
ADMA
BEAM
Price
$13.26
$20.92
Analyst Decision
Buy
Strong Buy
Analyst Count
4
15
Target Price
$18.00
★ $49.85
AVG Volume (30 Days)
★ 3.8M
2.1M
Earning Date
11-04-2026
11-03-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 82.31
EPS
★ 0.57
N/A
Revenue
★ $42,219,783.00
$24,000.00
Revenue This Year
$4.49
N/A
Revenue Next Year
$14.91
N/A
P/E Ratio
$23.39
★ N/A
Revenue Growth
★ 43.85
33.33
52 Week Low
$7.21
$20.44
52 Week High
$20.46
$38.26

Technical Indicators

Market Signals
Indicator
ADMA
BEAM
Relative Strength Index (RSI) 61.74 35.27
Support Level $7.84 N/A
Resistance Level $13.77 $27.30
Average True Range (ATR) 0.74 1.72
MACD 0.02 -0.61
Stochastic Oscillator 74.43 3.31

Price Performance

Historical Comparison
ADMA
BEAM

About ADMA ADMA Biologics Inc

ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The segments of the company are ADMA BioManufacturing, which generates maximum revenue, Plasma Collection Centres, and the corporate segment. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling & packing services. The company derives maximum revenue from the United States.

About BEAM Beam Therapeutics Inc.

Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company operates and manages its business in one operating segment, United States.

Share on Social Networks: